Drug discovery prospect from untapped species: Indications from approved natural product drugs

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Zhu, Feng ^a,b,c   Ma, Xiao Hua ^c   Qin, Chu ^c,d   Tao, Lin ^c,d   Liu, Xin ^c   Shi, Zhe ^c   Zhang, Cun Long ^a   Tan, Chun Yan ^a   Chen, Yu Zong ^a,c   Jiang, Yu Yang ^a  

^a TSINGHUA UNIVERSITY   (China)

^b CHONGQING UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ADENYLATE CYCLASE; ANIDULAFUNGIN; DAPTOMYCIN; ERIBULIN; ERLOTINIB; EXENDIN 4; FINGOLIMOD; FUMAGILLIN; GALANTAMINE; GEFITINIB; HESPERETIN; HIRULOG; IMATINIB; IXABEPILONE; LAPATINIB; LATANOPROST; MICAFUNGIN; MIGLITOL; MIGLUSTAT; NATURAL PRODUCT; NILOTINIB; OMEGA CONOTOXIN MVIIA; PAZOPANIB; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SUNITINIB; TETRAHYDROLIPSTATIN; TRABECTEDIN; TUBULIN; UNINDEXED DRUG;

ACTINOMYCETALES; AGARICUS BISPORUS; AMARYLLIDACEAE; ARTEMISIA DRACUNCULUS; ARTICLE; ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS UNILATERALIS; BERBERIDACEAE; BREVIBACILLUS; BREVIBACILLUS LATEROSPORUS; BYSSOCHLAMYS; CALLISTEMON CITRINUS; CITRUS; CITRUS BERGAMIA; CLITOPILUS SCYPHOIDES; COCONUT; COLEOPHOMA EMPETRI; CONIDIUM; CONUS GEOGRAPHUS; CONUS MAGUS; CORYLUS AVELLANA; CORYNEBACTERIUM DIPHTHERIAE; DRUG DEVELOPMENT; ECTEINASCIDIA TURBINATE; EMERICELLA; EMERICELLA RUGULOSA; FAMILIA; FUNGUS; GALANTHUS; GALANTHUS ELWESII; GALANTHUS NIVALIS; GALANTHUS WORONOWII; GENE CLUSTER; HAEMENTERIA OFFICINALIS; HALICHONDRIA OKANAI; HELODERMA SUSPECTUM; HIRUDO MEDICINALIS; ISARIA SINCLAIRII; LARREA TRIDENTATE; LEDENFELDIA CHONDRODES; LEMON; LENTZEA ALBIDA; LEONTICE LEONTOPETALUM; LEUCOJUM AESTIVUM; LIZARD; LYCORIS RADIATE; LYCORIS SQUAMIGERA; MAIZE; MAPPIA FOETIDA; MORUS ALBA; MOUSE; MYRTACEAE; NARCISSUS PSEUDONARCISSUS; NONHUMAN; OLACACEAE; OPHIORRHIZA PUMILA; PECTOBACTERIUM CHRYSANTHEMI; PENICILLIUM; PENICILLIUM BIALOWIEZENSE; PENICILLIUM CARNEUM; PENICILLIUM FAGI; PENICILLIUM ROQUEFORTI; PHARMACOPHORE; PLECTRANTHUS; PLECTRANTHUS BARBATUS; RUBIACEAE; SEIMATOANTLERIUM TEPUIENSE; SORANGIUM CELLULOSUM; SPECIES DIVERSITY; SPECIES EXTINCTION; SPECIES IDENTIFICATION; SPINACH; SPONGE (PORIFERA); STREPTOMYCES; STREPTOMYCES ACUMINATE; STREPTOMYCES ARGENTEOLUS; STREPTOMYCES FILAMENTOSUS; STREPTOMYCES HYGROSPICUS; STREPTOMYCES TESTACEUS; STREPTOMYCES TOXYTRICINI; STREPTOMYCES TSUKUBAENSIS; TAXUS BACCATA; TAXUS BREVIFOLIA; TAXUS WALLICHIANA; UNTAPPED SPECIES; UROCHORDATA; ZYGOPHYLLACEAE;

BIOLOGICAL AGENTS; CYANOBACTERIA; DRUG APPROVAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; FUNGI; HUMANS; INTELLECTUAL PROPERTY; MULTIGENE FAMILY; PLANTS;

EID: 84863850519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039782     Document Type: Article

References (37)

1. Li JW, Vederas JC, (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161-165.
2. Newman DJ, Cragg GM, (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477.
3. Tulp M, Bohlin L, (2002) Functional versus chemical diversity: is biodiversity important for drug discovery? Trends Pharmacol Sci 23: 225-231.
4. Berdy J, (2005) Bioactive microbial metabolites. J Antibiot (Tokyo) 58: 1-26.
5. Zhu F, Qin C, Tao L, Liu X, Shi Z, et al. (2011) Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci U S A 108: 12943-12948.
6. Bemis GW, Murcko MA, (1996) The properties of known drugs. 1. Molecular frameworks. J Med Chem 39: 2887-2893.
7. Koehn FE, Carter GT, (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206-220.
8. Tulp M, Bohlin L, (2005) Rediscovery of known natural compounds: nuisance or goldmine? Trends Pharmacol Sci 26: 175-177.
9. Watve MG, Tickoo R, Jog MM, Bhole BD, (2001) How many antibiotics are produced by the genus Streptomyces? Arch Microbiol 176: 386-390.
10. Harvey AL, (1999) Medicines from nature: are natural products still relevant to drug discovery? Trends Pharmacol Sci 20: 196-198.
11. Chiang YM, Chang SL, Oakley BR, Wang CC, (2011) Recent advances in awakening silent biosynthetic gene clusters and linking orphan clusters to natural products in microorganisms. Curr Opin Chem Biol 15: 137-143.
12. Wilkinson B, Micklefield J, (2007) Mining and engineering natural-product biosynthetic pathways. Nat Chem Biol 3: 379-386.
13. Projan SJ, (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6: 427-430.
14. Rappe MS, Giovannoni SJ, (2003) The uncultured microbial majority. Annu Rev Microbiol 57: 369-394.
15. Piel J, (2011) Approaches to capturing and designing biologically active small molecules produced by uncultured microbes. Annu Rev Microbiol 65: 431-453.
16. Bergmann S, Schumann J, Scherlach K, Lange C, Brakhage AA, et al. (2007) Genomics-driven discovery of PKS-NRPS hybrid metabolites from Aspergillus nidulans. Nat Chem Biol 3: 213-217.
17. Wenzel SC, Muller R, (2005) Formation of novel secondary metabolites by bacterial multimodular assembly lines: deviations from textbook biosynthetic logic. Curr Opin Chem Biol 9: 447-458.
18. Pullen CB, Schmitz P, Hoffmann D, Meurer K, Boettcher T, et al. (2003) Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia. Phytochemistry 62: 377-387.
19. Schroeckh V, Scherlach K, Nutzmann HW, Shelest E, Schmidt-Heck W, et al. (2009) Intimate bacterial-fungal interaction triggers biosynthesis of archetypal polyketides in Aspergillus nidulans. Proc Natl Acad Sci U S A 106: 14558-14563.
20. Baltz RH, (2008) Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 8: 557-563.
21. Sayers EW, Barrett T, Benson DA, Bryant SH, Canese K, et al. (2009) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 37: D5-15.
22. Clardy J, Fischbach MA, Walsh CT, (2006) New antibiotics from bacterial natural products. Nat Biotechnol 24: 1541-1550.
23. Dann JG, Stammers DK, Harris CJ, Arrowsmith RJ, Davies DE, et al. (1986) Human renin: a new class of inhibitors. Biochem Biophys Res Commun 134: 71-77.
24. Furet P, Caravatti G, Lydon N, Priestle JP, Sowadski JM, et al. (1995) Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput Aided Mol Des 9: 465-472.
25. Adachi K, Kohara T, Nakao N, Arita M, Chiba K, et al. (1995) Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720. Bioorganic & Medicinal Chemistry Letters 5: 853-856.
26. Hunt JT, (2009) Discovery of ixabepilone. Mol Cancer Ther 8: 275-281.
27. Kingston DG, (2009) Tubulin-interactive natural products as anticancer agents. J Nat Prod 72: 507-515.
28. Wall ME, Wani MC, (1995) Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55: 753-760.
29. Gambacorti-Passerini C, (2008) Part I: Milestones in personalised medicine-imatinib. Lancet Oncol 9: 600.
30. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
31. Lydon NB, Druker BJ, (2004) Lessons learned from the development of imatinib. Leuk Res 28: S29-38.
32. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, et al. (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248: 358-361.
33. McQuade TJ, Tomasselli AG, Liu L, Karacostas V, Moss B, et al. (1990) A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247: 454-456.
34. Ralph RK, McCombs PJ, Tener G, Wojcik SJ, (1972) Evidence for modification of protein phosphorylation by cytokinins. Biochem J 130: 901-911.
35. Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, et al. (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224: 771-786.
36. Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, et al. (1996) 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 39: 2285-2292.
37. Nakano H, Omura S, (2009) Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine. J Antibiot (Tokyo) 62: 17-26.